使用皮下注射α-干扰素治疗2019年新型冠状病毒可能性的循证快速评估 / Evidence-Based Rapid Assessment of Hypodermic Injection of Alpha-Interferon in Treatment of Novel Coronavirus Pneumonia in 2019

ABSTRACT:

OBJECTIVE:

The study aims to conduct a rapid systematic evaluation of antiviral treatments in Critical Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS), and to explore the clinical possibility of subcutaneous injection of alpha-interferon for the 2019 novel coronavirus (2019-NCoV) pneumonia Journal Full Text Database (CNKI), Wip Chinese Science and Technology Journal Full-Text Database (VIP), Wanfang Database (Wangfang Data), Chinese Biomedical Literature Database (CBM), Cochrane library, PubMed etc.. In addition, retrieving WHO and CDC websites, National Health Commission websites, relevant national releases Diagnostic regimens (c) Evidence evaluation and data extraction according to evidence-based pharmacological methods obtained 1502 articles were retrieved and eventually included in 11 studies. Results suggest: ① Early use of subcutaneous injection alpha-interferon, as far as possible in the confirmed coronavirus After infection 48 h use, with the extension of the time of medication and the time of diagnosis, effective Reduced, so treatment as early as possible .2. No statistically significant difference in treatment effect between various types of interferon .3. Subcutaneous injection of alpha-interferon in combination with ribavirin has been proven effective in individual studies, but need to be wary of its adverse reaction. adverse reactions are more tolerable to drop in hemoglobin, elevated transaminasinases, Amylase is elevated, but most do not affect treatment. concluded that subcutaneous injection of alpha-interferon can be used as a Experimental therapies are used in antiviral treatment of novel coronavirus pneumonia, especially in newly infected persons, and randomized controlled trials and real-world clinical studies should be conducted as soon as possible to further explore the clinical effects of alpha-interferon for novel coronavirus pneumonia.